Articles tagged with: Pomalidomide
News»
The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.
More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”
The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell disorders”).
The …
News»
Celgene Corporation announced this morning that it has completed submission of its application to the U.S. Food and Drug Administration (FDA) for the approval of pomalidomide as a treatment for relapsed and refractory multiple myeloma.
If the FDA approves pomalidomide based on this application, Celgene could begin marketing pomalidomide in the United States as early as this fall.
Pomalidomide (Pomalyst), which belongs to the same class of drugs as thalidomide (Thalomid) and Revlimid (lenalidomide), is being developed by Celgene (NASDAQ: CELG) for the treatment of multiple myeloma and myelofibrosis.
Results from …
NewsFlash »
Progression From MGUS To Myeloma Is Similar Among Japanese And Westerners – A recent study found that Japanese people with monoclonal gammopathy of undetermined significance (MGUS) progressed to multiple myeloma at rates similar to those previously reported for Westerners. Specifically, the results showed that 3 percent progressed within 5 years, 9 percent within 10 years, 11.4 percent within 15 years, and 32.1 percent within 20 years. For more information, see the study in the journal Rinsho Ketsueki (abstract).
Pomalidomide May Be Effective In Patients With Amyloidosis – Results from a Phase 2 study show that pomalidomide plus dexamethasone (Decadron), a combination being studied for the treatment of multiple myeloma, may also be effective in previously treated patients with immunoglobulin light chain amyloidosis. Amyloidosis is a blood disorder that results in the abnormal accumulation of proteins in tissues and organs throughout the body. An estimated 10 percent to 15 percent of myeloma patients also develop symptoms associated with amyloidosis (see related Beacon news). Among the 33 amyloidosis patients included in the study, 48 percent had improved blood cell counts and 15 percent had organ improvement after treatment with pomalidomide and dexamethasone. The median progression-free survival was 14 months, and the median overall survival was 28 months. For more information, see the study in the journal Blood (abstract).
Participants Needed For Myeloma Risk Association Study – The International Myeloma Foundation is conducting a study to determine why certain races and family members are at an increased risk of developing multiple myeloma. The study is a brief survey that multiple myeloma patients can complete via the Internet. To participate, see the study website.
Clinical Insights Education Program – The Multiple Myeloma Research Foundation (MMRF) is sponsoring an education program for myeloma patients and their families about multiple myeloma clinical insights. The event will be held on April 27 in New York City. Myeloma experts from leading cancer centers will speak about the latest advances in frontline therapy, stem cell transplants, relapsed and refractory myeloma, supportive care, and clinical trials. A question and answer session is included in the program. Registration will begin at 9 a.m., and the program will conclude at 2:30 p.m. For more information or to register, please see the MMRF website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
Many new and promising research developments occurred in the field of multiple myeloma during 2011. Over the course of the year, The Myeloma Beacon published nearly 100 articles on important myeloma-related studies.
To identify the most important of these studies from 2011, The Myeloma Beacon surveyed leading physicians and researchers in the field. They were asked to name the three peer-reviewed journal articles published in 2011 and the three conference presentations from 2011 that have the most important findings or implications relating to multiple myeloma.
Their selections for the most important journal …
News»
Celgene announced this morning that it plans to submit an application for the approval of pomalidomide for relapsed and refractory multiple myeloma to the U.S. Food and Drug Administration (FDA) during the first quarter of 2012.
In addition, the company said that it plans to submit a similar application to the European Medicines Agency (EMA) during the first half of this year.
The updated submission timeline means that pomalidomide could be approved for use in the United States and in Europe by the end of this year.
Celgene's announcement was made in a …
News»
Pomalidomide was one of the potential new myeloma treatments in the spotlight at the 2011 meeting of the American Society of Hematology (ASH) held earlier this month.
The consensus is that the drug, a chemical relative of thalidomide and Revlimid, performed well during its time on the stage.
Research findings about pomalidomide (Pomalyst) were summarized in four of the meeting’s oral presentations and a number of poster presentations.
Most of these presentations examined pomalidomide’s efficacy and safety as a potential treatment for relapsed and refractory myeloma patients.
Physicians …
News»
What were the myeloma-related "hidden gems" of the recent American Society of Hematology (ASH) annual meeting, which ended two weeks ago?
The Beacon asked exactly this question of its Medical Advisors -- the myeloma specialists who generously share their knowledge and expertise in the Beacon's myeloma discussion forum.
And the responses from the Advisors were surprising.
Surprising, because they were so similar.
The three Advisors who responded to the Beacon's question independently picked the same "hidden gem" -- specifically, the research presented at the meeting showing that the protein …